Unlocking the Genetic Mysteries of Alopecia Areata

Alopecia areata (AA) is an enigmatic autoimmune condition characterized by non-scarring hair loss. Its global prevalence highlights a significant impact on individuals of all ages, manifesting in various forms from patchy hair loss (alopecia areata) to complete hair loss on the scalp (alopecia totalis) or the entire body (alopecia universalis). The unpredictable nature of this condition not only affects physical appearance but also carries psychological ramifications, necessitating a deeper understanding of its etiology, particularly its genetic underpinnings.

Genetic Underpinnings: Genetic disorders can be divided into three main categories: monogenic, chromosomal, and polygenic/multifactorial. Monogenic diseases, of which there are between 5,000 and 8,000 we know about, adhere to Mendelian inheritance patterns and involve a single gene responsible for the disease. Understanding how these genes cause a disease is relatively straight forward as one gene equals one disease. Of course in real life it is more complicated than that as the environment can play a role, but fundamentally single gene diseases follow a direct inheritance pattern modified by whether the gene is dominant (shows up in every generation) or recessive (needs 2 copies of the gene, one from each parent, to come together in a child before the disease appears).

Alopecia Areata as a Multi-Gene condition: In contrast, most diseases, including many common ones, are polygenic. This means their development is influenced by the interplay of multiple genes, with the added complication that the environment can modify the effects of each of the genes involved. This makes it much harder to understand patterns of inheritance and to figure out which genes are the most important in causing the disease. AA is acknowledged as a polygenic disease with a complex genetic framework. It shares genetic susceptibility with other inflammatory conditions, meaning some of the genes involved in AA are also found active in other autoimmune diseases. This underscores the interconnected nature of autoimmune pathologies and goes some way to explaining why people with AA are also susceptible to developing other conditions – particularly rheumatoid arthritis and autoimmune thyroiditis.

Key Genetic Factors in AA: There a quite a few single gene studies published on AA since as far back as the 1980s. However, there is a problem with single gene studies in that it requires researchers to guess which genes might be important in a disease and then pick one of them to study. Single gene studies are relatively easy to do, but they risk missing more important genes that could be much more significant in the mechanism of alopecia areata development. Still, these single gene studies have suggested that the majority of genes identified in alopecia areata are connected to immune system functions, particularly those involving CD4+ regulatory T cells (Tregs), CD8+ effector T cells, antigen presentation, and natural killer (NK) cell activities. Key genes in this context include FOXP3, ICOSLG, MICA, MIF, various HLA subtypes, IL7RA, IL1RN, AIRE, KRT82, SOCS1, NFKB, and RAG. These genes play a critical role in the disease’s development and have been extensively studied in the context of AA, often through analyses of serum or skin samples from affected areas.

Genome Wide Association Studies: To really identify which genes are the most important in a polygenic disease requires a different approach – something called a genome wide association study (GWAS). GWAS studies are much bigger and more challenging to do compared to single gene studies. It involves collecting blood samples from several thousand people (and a similar number of controls for comparison) and then screening every sample across the entire human genome of around 25,000 functional genes. By making a comparison to a control group, scientists can see if any genes are identified much more frequently in patients with AA. Because of the scale involved, and the cost, only two GWAS studies have been done for alopecia areata; one in the USA and one in Europe.

Two Big GWAS Studies for Alopecia Areata: The initial study in 2010 involved 1,054 AA patients and 3,278 controls, identifying 139 Single Nucleotide Polymorphisms (SNPs) across eight gene regions (loci). A subsequent study in 2012, incorporating 1,702 Central European patients and 1,723 controls, confirmed five of these loci and explored 12 additional ones. The genes identified were grouped based on their association with the immune system, hair follicle function, or other categories. Additionally, investigations into copy number variants (CNVs), which refer to the number of copies of a gene present in an individual, were integrated into the GWAS studies. A study including over 16,000 AA patients and controls found that CNVs influenced the expression of fourteen genes. It should be noted that not every person in the studies had all the genes for AA susceptibility. A few had no susceptibility genes, most had a few genes – with different combinations seen in different people. At the other end of the bell curve there were a few people with all the susceptibility genes. Overall, 14 candidate gene loci have been found associated with AA (it’s possible that more than one gene is active at each locus/location). There are probably more, but to find them would need much larger studies with many more people involved. Below are some summaries of some of the genes found so far.

Immune Function Genes: Research through Genome-Wide Association Studies (GWAS) on alopecia areata (AA) has pinpointed several genes crucial for immune regulation as key factors in the disease’s pathology. These include CTLA-4 and IL2RA, vital for T cell regulation and immune tolerance; IKZF4, which is essential in regulatory T cell function; and ULBP genes, linked to natural killer cell activity and autoimmunity risk. Some cytokine genes have been found, including IL-2/21 and IL13, involved in activation of immune system cells. Additionally, several HLA subtypes have been identified; the HLA system is important in presenting antigens to the immune system so the immune cells can recognise and respond to different proteins. Finding these immune function genes are present in some patients underscores the genetic basis of immune system dysregulation seen in AA development.

Hair Growth Function Genes: In GWAS studies, STX17 showed a strong correlation with alopecia areata (AA). STX17 is noted for its expression in hair follicles and association with hair graying in horses (probably also humans), suggesting its role in the disease’s tendency to affect pigmented hair. Additionally, KRT82, identified through whole genome sequencing, is linked to AA. This gene, responsible for producing a keratin protein during the hair growth’s anagen phase, sees diminished expression in AA, aligning with the observed targeted attack on hair follicles during this phase.

General Function Genes: PRDX5, associated with AA in GWAS studies, encodes an antioxidant enzyme that plays a crucial role in cellular protection against oxidative stress. Its overexpression can protect cells from death due to toxic peroxides, while its under-expression makes cells more vulnerable to oxidative damage. This is relevant to AA, as patients exhibit higher levels of oxidative stress markers, such as malondialdehyde, which increases with the disease’s duration and severity, indicating a link between oxidative stress and AA pathogenesis.

Pathogenesis and Immune Response: It is clear that the two GWAS studies have been instrumental in pinpointing specific genetic loci associated with AA, broadening our understanding of its genetic basis. These studies have not only identified new genetic variants but have also reinforced the link between AA and other autoimmune disorders. This has implications for potential therapeutic targets, as understanding these genetic intersections may lead to novel treatments that can address multiple autoimmune conditions simultaneously. The pathogenesis of AA involves a complex interplay of genetic predisposition and environmental factors leading to the breakdown of the immune privilege of hair follicles. This process results in an autoimmune attack on the hair follicles, manifesting as hair loss. The exact triggers for this breakdown remain a subject of active research, but genetic predisposition to AA onset is a critical factor for disease development.

Clinical Implications: The implications of these genetic findings are significant for clinical practice. They offer potential for more precise diagnosis and personalized treatment approaches based on individual genetic profiles. For instance, it may be possible to test a patient to find out which AA susceptibility genes are present. Studies are already beginning to emerge where the degree of response to treatments like JAK inhibitors are evaluated in people with known genetic profiles. It is quite likely that people with some gene profiles will be more responsive to a particular treatment than others with a different gene profile. Knowing someone’s gene profile could allow a dermatologist to select a treatment that is most likely to work for that particular patient’s gene susceptibility profile. Further, new therapies could be developed that very specifically target gene encoded immune pathways implicated in AA. Such targeted therapy should be more effective and have fewer side effects than current treatments. This personalized approach to treatment aligns with the broader trend in medicine towards precision healthcare.

Future Research: The future of AA research lies in further unraveling the genetic complexities of the disease. This includes not only identifying more genetic factors, but also understanding how these genes interact with each other and with environmental factors. A person’s genetic makeup is only part of story in terms of how AA develops. We know that there also has to be a significant contribution from the environment to trigger the actual onset of the hair loss and also to determine the pattern of AA. Someone can have several genes for AA susceptibility, yet never develop the condition because they are never exposed to the relevant environmental triggers. Equally, someone may have only one or two susceptibility genes for AA, but if they receive a particularly strong environmental trigger, they develop AA. Much more work is needed to understand the functions of the genes in the development of alopecia areata, how they interact with each other, and how they are affected by environmental factors. Such research could lead to breakthroughs in treatment, potentially even preventing the onset of the disease in genetically predisposed individuals.

Conclusion: In conclusion, the exploration of the genetic underpinnings of alopecia areata is a rapidly evolving field that holds great promise for the millions affected by this condition. The advances in genetic research have already provided invaluable insights into the pathogenesis of AA and are paving the way for more effective and personalized treatments. As we continue to unravel the genetic mysteries of AA, the hope for a cure grows ever stronger.

Bibliography